Days
Hours
Minutes
Seconds
-40%
on all subscriptions*
Last hours
Enjoy this offer
* See conditions under "Our services"

Valuation: GENFIT

Market Cap 498M 0 572M 459M 432M 808M 53.86B 813M 5.46B 2.12B 26.54B 2.15B 2.1B 92B P/E 2025
-3.06x
P/E 2026 * 52.6x
Enterprise Value 443M 0 509M 409M 384M 719M 47.94B 724M 4.86B 1.89B 23.63B 1.91B 1.87B 81.89B EV / Sales 2025
2.34x
EV / Sales 2026 * 4.74x
Free-Float
86.88%
Yield 2025 *
-
Yield 2026 * -
Manager TitleAgeSince
Chief Executive Officer 58 16/09/2019
Director of Finance/CFO 52 22/04/2021
Chief Tech/Sci/R&D Officer - 27/11/2025
Director TitleAgeSince
Chairman 70 16/06/2017
Director/Board Member 54 15/09/1999
Director/Board Member 58 16/06/2017
Change 5-day change 1-year change 3-year change Capi.($)
-0.34%-1.48%-12.18%-13.39% 43.44B
+3.31%+9.22%+308.19%+534.70% 33.54B
-1.70%-7.34%+8.51%-21.94% 28.48B
+2.84%+3.80%+6.87%+41.02% 29.2B
-0.57%+3.77%+12.66%+20.42% 25.34B
-0.14%+7.06% - - 14.36B
+0.68%-3.13%+52.04%+104.27% 13.05B
+0.54%-3.88%+3.69%+2.24% 12.67B
-0.26%+0.41%+100.27%+80.47% 12.28B
Average +0.56%+0.80%+60.01%+93.47% 23.6B
Weighted average by Cap. +0.71%+0.79%+63.28%+105.15%

Financials

2025 2026 *
Net sales 66.82M 0 76.69M 61.59M 57.93M 108M 7.23B 109M 733M 285M 3.56B 288M 282M 12.34B 95.2M 0 109M 87.75M 82.54M 154M 10.3B 156M 1.04B 405M 5.07B 410M 401M 17.59B
Net income -8.3M -0 -9.53M -7.65M -7.2M -13.47M -898M -13.56M -91.05M -35.36M -443M -35.77M -35M -1.53B 18.31M 0 21.01M 16.88M 15.87M 29.69M 1.98B 29.9M 201M 77.97M 976M 78.86M 77.17M 3.38B
Net Debt -54.72M -0 -62.8M -50.44M -47.45M -88.76M -5.92B -89.39M -600M -233M -2.92B -236M -231M -10.11B -46.87M -0 -53.79M -43.2M -40.64M -76.03M -5.07B -76.56M -514M -200M -2.5B -202M -198M -8.66B
Logo GENFIT
GENFIT is a biopharmaceutical company in late-stage development focused on the discovery and development of innovative therapeutic and diagnostic solutions in the field of liver diseases, particularly of metabolic origin, where unmet medical needs are considerable, in particular due to a lack of approved treatments. GENFIT is a leading innovator in the field of nuclear receptor-based drug discovery with a rich history and a solid scientific heritage spanning nearly two decades. The company has offices in Lille, Paris, Zurich and Cambridge, MA (USA).
Employees
-
Trader
Investor
Global
Quality
ESG MSCI
-
LAST HOURS | 40% Discount: The Best Subscriber-Only Tools to Unlock Hidden Opportunities!
d
:
:
SEIZE THE OFFER!